Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension. 2008

S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
Hôpital Antoine Beclere, 157 rue de la Porte de Trivaux, 92140 Clamart, France. steve.provencher@crhl.ulaval.ca

Improvement in exercise capacity may not be associated with significant changes in resting pulmonary haemodynamics. The present prospective study documented the relationships between improvement in 6-min walking distance (6MWD) and changes in resting and exercise pulmonary haemodynamics after treatment in patients with idiopathic pulmonary arterial hypertension (IPAH). A total of 42 IPAH patients underwent supine submaximal exercise haemodynamic assessments at baseline and after 5+/-2 months of therapy. The 6MWD, the corresponding chronotropic response (peak minus resting heart rate), and resting and exercise haemodynamic variables were analysed. The isoflow was defined as the lowest of the pre- and post-treatment peak cardiac index (CI). The extrapolated isoflow mean pulmonary artery pressure ((pa)) was used to characterise changes in (pa)-CI regression lines following treatment. Patients were given bosentan (n = 28), epoprostenol (n = 12) or both. The 6MWD increased significantly, from 399+/-88 to 442+/-86 m. On univariate analysis, changes in 6MWD correlated with changes in isoflow (pa), chronotropic response, resting haemodynamics (CI, pulmonary vascular resistance and mixed venous oxygen saturation) and exercise haemodynamics (peak CI). On multivariate analysis, only changes in isoflow (pa) and chronotropic response were independently associated with changes in 6MWD. Improvement in exercise tolerance with chronic therapy is independently related to improvement in pulmonary haemodynamics measured in exercise but not in resting conditions.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077300 Bosentan A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS. 4-t-Butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide,Bosentan Anhydrous,Bosentan Monohydrate,Ro 47-0203,Ro-47-0203,Tracleer,Ro 47 0203,Ro 470203
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
August 2013, The European respiratory journal,
S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
January 1975, Cor et vasa,
S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
May 2021, The European respiratory journal,
S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
February 2014, The European respiratory journal,
S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
December 2023, The American journal of cardiology,
S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
January 2024, The European respiratory journal,
S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
January 2019, Pulmonary circulation,
S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
August 2013, International journal of cardiology,
S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
May 2017, Annals of the American Thoracic Society,
S Provencher, and P Hervé, and O Sitbon, and M Humbert, and G Simonneau, and D Chemla
April 2012, International journal of cardiology,
Copied contents to your clipboard!